{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:52:00Z","timestamp":1790373120911,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1465,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1111\/j.1365-2133.2011.10411.x","type":"journal-article","created":{"date-parts":[[2011,5,17]],"date-time":"2011-05-17T02:38:22Z","timestamp":1305599902000},"page":"646-651","source":"Crossref","is-referenced-by-count":60,"title":["Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients"],"prefix":"10.1093","volume":"165","author":[{"given":"J.H.","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-C.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,8,28]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaut.2008.08.003","article-title":"Advances in pemphigus and its endemic pemphigus foliaceus (fogo selvagem) phenotype: a paradigm of human autoimmunity","volume":"31","author":"Culton","year":"2008","journal-title":"J Autoimmun"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2010.02.052","article-title":"Therapeutic ladder for pemphigus vulgaris: emphasis on achieving complete remission","volume":"64","author":"Strowd","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.132.2.203","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0190-9622(00)90213-5","article-title":"Patterns of remission in pemphigus vulgaris","volume":"42","author":"Herbst","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB11|cit11","first-page":"269","article-title":"Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20 (+) follicular lymphoma-associated paraneoplastic pemphigus","volume":"137","author":"Borradori","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaad.2009.09.045","article-title":"Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease","volume":"64","author":"Li","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.det.2010.03.002","article-title":"Innovative uses of rituximab in dermatology","volume":"28","author":"Carr","year":"2010","journal-title":"Dermatol Clin"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000099591","article-title":"Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)","volume":"214","author":"Marzano","year":"2007","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin\u2019s lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2011.10411.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10411.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10411.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T08:52:23Z","timestamp":1676364743000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/165\/3\/646\/6644131"}},"subtitle":["Doses of rituximab in pemphigus treatment"],"short-title":[],"issued":{"date-parts":[[2011,8,28]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10411.x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.716197960.791552864","asserted-by":"object"}]},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,28]]}}}